Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04953078
Other study ID # PT-CR-001
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date September 11, 2021
Est. completion date November 4, 2022

Study information

Verified date January 2023
Source Baiya Phytopharm Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is a phase 1, open-label, randomized, first-in-human clinical trial to evaluate the safety, tolerability and reactogenicity of escalating doses of Baiya SARS-CoV-2 VAX1 vaccine in participants aged 18-60 for adult groups and 61-75 for elderly groups. Each group will consist of three cohorts to evaluate different doses (low, medium, high) of Baiya SARS-CoV-2 VAX vaccine. Participants will be injected with two doses of the investigational product with a 21-day interval.


Recruitment information / eligibility

Status Completed
Enrollment 48
Est. completion date November 4, 2022
Est. primary completion date December 2, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Healthy man and woman between 18-60 years old (inclusive) for the adult cohort and between 61-75 years old (inclusive) for the elderly cohort. - Have a body-mass index of 18.0-30.0 kg/m² at screening - Give informed consent prior to study enrollment and all study procedures - Participants must be able to comply with study procedures and be available for all study visits - Participants must be in general good health based on medical history and physical examination as determined by the investigator(s) at Screening - Participants must have haematology, clinical chemistry, coagulation, and urinalysis test results that are not deviating from the normal reference range by age and gender, or considered "not clinicallysignificant" per investigator decision based on safety at Screening. - Males must be surgically sterile (>30 days since vasectomy with no viable sperm), practice true abstinence, or, if engaged in sexual activities with a female with childbearing potential, use condoms from first vaccination until 60 days after the last vaccination. - Females of child-bearing potential must practice true abstinence, or, if engaged in sexual activities with a male, agree to use highly effective (failure rate of <1% per year when used consistently and correctly), double-barrier contraceptive measures throughout the study and intend to continue use of contraception methods for at least 60 days following the last vaccination. - Female participants of child-bearing potential must have negative serum pregnancy test by beta human chorionic gonadotropin [ß-HCG] at Screening and a negative urine-based pregnancy test within 24 hours prior to each investigational vaccine administration - Female participants of childbearing potential must not be pregnant or breastfeeding. - Women of non-child-bearing potential must: 1. be classified as being postmenopausal (defined as having a history of amenorrhea for at least one year), or 2. where history of amenorrhea is less than one year, female participants must have a follicle stimulating hormone (FSH) level > 40 milli-international units per millilitre (mIU/mL), or 3. have a documented status of being surgically sterile (hysterectomy, bilateral oophorectomy, or /salpingectomy). - All volunteers will be screened for serum antibodies against SARS-CoV-2, as evidence of previous infection using Enzyme-Linked Immunosorbent Assay (ELISA) and must have a negative result - Body temperature measured at forehead using validated device must be less than 37.5ºC at Screening. - Pulse must be no greater than 100 beats per minute, at Screening - Systolic blood pressure (SBP) must be between 85 to 150 millimeters of mercury (mm Hg), inclusive, at Screening - Participants must agree to refrain from donating blood, plasma, ovules, sperm, or organs during the whole study Exclusion Criteria: - Presence of clinically significant medical history, unstable chronic or acute disease, or physical, or laboratory findings that in the opinion of the PI may potentially increase the expected risk of exposure to the investigational vaccine, compromise the safety of the participant, or interfere with any aspect of study conduct or interpretation of results. This will include any thrombocytopenia or bleeding disorder contraindicating IM vaccination. - Presence of self-reported or medically documented significant medical or psychiatric condition(s) as judged by the investigator(s) that it may not be in the participant's interest to participate in the study. - Presence of an acute illness, as determined by the participating Study Site investigator(s), with or without fever (forehead temperature measured by validated device = 37.5 ºC) within 72 hours prior to each vaccination - Presence of birthmarks, tattoos, wound, or other skin conditions over the deltoid region of both arms that in the opinion of the investigator(s), could reasonably obscure and interfere with evaluation of local ISRs - Inadequate venous access to allow collection of blood samples - Breastfeeding or planning to breastfeed from the time of the first vaccination to after the last vaccination, or pregnant as confirmed by a positive serum ß-HCG pregnancy test at Screening or positive urine pregnancy test at subsequent clinic visits at timepoints as delineated in the schedule of assessments - Received any prophylactic or therapeutic vaccine, or licensed or unlicensed vaccine, device, or blood product, within 4 weeks of first vaccination or 5 half-lives (whichever is longer), or anticipate to do so in the follow-up period defined for this study - History of severe allergy (requiring hospital care), anaphylaxis, severe reaction to any drug or prior vaccination, or any known or suspected allergies or sensitivities to any component of the investigational vaccine or tobacco - Participant is immunosuppressed as caused by disease (such as HIV) - Chronic use (more than 14 continuous days) of or anticipated need to use, within the next 6 months, of any medications that may be associated with impaired immune responsiveness or with immunosuppression - History of hepatitis B or hepatitis C infection - Receipt of immunoglobulins or blood products within 90 days of the first vaccination - Requirement for antipyretic or analgesic medication on a daily or every other day basis from enrolment through 72 hours after vaccination - Current use of any prescription or over-the-counter medications within 7 days prior to vaccination, unless approved by the PI - Receipt of other investigational products (drug, biologic or device) within 60 days before the first vaccination - History of alcohol or drug abuse that in the opinion of the PI could affect the participant's safety or compliance with study - Participant is unwilling to abstain from blood donation during the course of the study, and/or is participating in any research study involving blood sampling (more than 450 mL /unit of blood), or blood donation to any blood bank during the 2 months prior to the Screening visit - Participant is unwilling to abstain from donating plasma, ovules, sperm, or organs during the course of the study - Close contact with anyone known to have SARS-CoV-2 infection within 30 days prior to vaccine administration - History of COVID-19 diagnosis - Has a positive result on SARS-CoV-2 antibody IgG/IgM measured by ELISA at screening - On current treatment with investigational agents for prophylaxis of COVID-19 including COVID-19 Vaccine under EUA. - Planning to travel out of the country from enrolment through 29 days after the second vaccination - Residing in a nursing home or other skilled nursing facility or having a requirement for skilled nursing care - Is a participant at high risk of SARS-CoV2 exposure in the opinion of the PI, including but not limited to an occupation (e.g., healthcare workers, active health care workers with direct patient contact, emergency response personnel) or close contact with a SARS-CoV-2 positive confirmed case (e.g. family member, housemate) - A chronic smoker (defined as =10 Pack years [packs/day × years smoked]) within the 12 months prior to enrolment (For Elderly Participants only)

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Baiya SARS-CoV-2 Vax 1
Intramuscular injection in the deltoid region of 0.5 mL/dose of Baiya SARS-CoV-2 Vax 1 (recombinant SARS-CoV-2 receptor-binding domain fused with FC region of human IgG1 vaccine)

Locations

Country Name City State
Thailand Chula Clinical Research Center (Chula CRC), Faculty of Medicine, Chulalongkorn University Bangkok
Thailand Queen Saovabha Memorial Institute Bangkok

Sponsors (2)

Lead Sponsor Collaborator
Baiya Phytopharm Co., Ltd. National Vaccine Institute, Thailand

Country where clinical trial is conducted

Thailand, 

Outcome

Type Measure Description Time frame Safety issue
Primary Frequency and Grade of Solicited Adverse Events 7 days after each vaccination
Primary Frequency and Grade of Adverse Events (including both solicited and unsolicited AEs) Up to 28 days after second vaccination
Primary Incidence of Serious Adverse Events (SAEs), Medically-Attended Adverse Events (MAAEs), and New-Onset Chronic Medical Conditions (NOCMCs) Up to 28 days after second vaccination
Primary Changes in Blood Pressure (Systolic and Diastolic Blood Pressure) from Baseline Blood pressure is measured mmHg. Blood pressure, both systolic and diastolic, at multiple timepoints according to the protocol will be compared to baseline value. Changes in blood pressure will be described using descriptive statistic (mean, standard deviation). Up to 28 days after second vaccination
Primary Changes in Pulse Rate from Baseline Pulse rate is measured as beats per minute. Pulse rate at multiple timepoints according to the protocol will be compared to baseline value. Changes in pulse rate will be described using descriptive statistic (mean, standard deviation). Up to 28 days after second vaccination
Primary Changes in Respiratory Rate from Baseline Respiratory rate is measured as breaths per minute. Respiratory rate at multiple timepoints according to the protocol will be compared to baseline value. Changes in respiratory rate will be described using descriptive statistic (mean, standard deviation). Up to 28 days after second vaccination
Primary Changes in Body Temperature from Baseline Body temperature is measured as degree Celsius. Body temperature at multiple timepoints according to the protocol will be compared to baseline value. Changes in body temperature will be described using descriptive statistic (mean, standard deviation) Up to 28 days after second vaccination
Primary Changes in Physical Conditions from Baseline Physical Examinations Baseline physical examination will include head, ears, nose, throat, lungs, lymph nodes, heart, abdomen and skin. Symptom directed physical examination will be performed for each subsequent visit. Changes in physical conditions from baseline physical examination will be described. Up to 28 days after second vaccination
Primary Safety Laboratory Value (Haematology) Haematology laboratory value by Common Terminology Criteria for Adverse Event (CTCAE) scale version 5.0 (absolute and change from baseline where identified). The scale ranges from Grade 1 (Mild) to Grade 5 (Most Severe). Up to 28 days after second vaccination
Primary Safety Laboratory Value (Serum chemistry) Serum Chemistry laboratory value by Common Terminology Criteria for Adverse Event (CTCAE) scale version 5.0 (absolute and change from baseline where identified). The scale ranges from Grade 1 (Mild) to Grade 5 (Most Severe). Up to 28 days after second vaccination
Primary Safety Laboratory Value (Coagulation) Coagulation laboratory value by Common Terminology Criteria for Adverse Event (CTCAE) scale version 5.0 (absolute and change from baseline where identified). The scale ranges from Grade 1 (Mild) to Grade 5 (Most Severe). Up to 28 days after second vaccination
Primary Safety Laboratory Value (Urinalysis) Urinalysis laboratory value by Common Terminology Criteria for Adverse Event (CTCAE) scale version 5.0 (absolute and change from baseline where identified). The scale ranges from Grade 1 (Mild) to Grade 5 (Most Severe). Up to 28 days after second vaccination
Primary Treatment-emergent Changes in Blood Pressure Grade of treatment-emergent changes in blood pressure by Common Terminology Criteria for Adverse Event (CTCAE) scale version 5.0. The scale ranges from Grade 1 (Mild) to Grade 5 (Most Severe). Up to 28 days after second vaccination
Primary Treatment-emergent Changes in Pulse Rate Grade of treatment-emergent changes in pulse rate by Common Terminology Criteria for Adverse Event (CTCAE) scale version 5.0. The scale ranges from Grade 1 (Mild) to Grade 5 (Most Severe). Up to 28 days after second vaccination
Primary Treatment-emergent Changes in Respiratory Rate Grade of treatment-emergent changes in respiratory rate by Common Terminology Criteria for Adverse Event (CTCAE) scale version 5.0. The scale ranges from Grade 1 (Mild) to Grade 5 (Most Severe). Up to 28 days after second vaccination
Primary Treatment-emergent Changes in Body Temperature Grade of treatment-emergent changes in body temperature by Common Terminology Criteria for Adverse Event (CTCAE) scale version 5.0. The scale ranges from Grade 1 (Mild) to Grade 5 (Most Severe). Up to 28 days after second vaccination
Primary Treatment-emergent, Changes in Physical Conditions Baseline physical examination will include head, ears, nose, throat, lungs, lymph nodes, heart, abdomen and skin. Symptom directed physical examination will be performed for each subsequent visit. Grade of treatment-emergent changes by Common Terminology Criteria for Adverse Event (CTCAE) scale version 5.0. The scale ranges from Grade 1 (Mild) to Grade 5 (Most Severe). Up to 28 days after second vaccination
Secondary Frequency and Grade of Medically-Attended Adverse Events (MAAEs) 28 days - 1 year after second vaccination
Secondary Frequency and Grade of New-Onset Chronic Medical Conditions (NOCMCs) 28 days - 1 year after second vaccination
Secondary Incidence of SAEs 28 days - 1 year after second vaccination
Secondary Geometric Mean Titer (GMT) of SARS-CoV-2 Specific Serum Neutralising Antibody SARS-CoV-2 Specific Serum Neutralising Antibody as measured by Micro-neutralization assay, expressed as GMTs for each cohort Up to 28 days after second vaccination
Secondary Geometric Mean Fold Rise (GMFR) of SARS-CoV-2 Specific Serum Neutralising Antibody SARS-CoV-2 Specific Serum Neutralising Antibody as measured by Micro-neutralization assay, expressed as GMFRs for each cohort Up to 28 days after second vaccination
Secondary Seroconversion Rate of SARS-CoV-2 Specific Serum Neutralising Antibody Seroconversion Rate is defined as the proportion of participants who achieves a greater than or equal to 4-fold rise in SARS-CoV-2 specific serum neutralising antibody level from baseline Up to 28 days after second vaccination
Secondary Geometric Mean Titer (GMT) of SARS-CoV-2 Surrogate Viral Neutralising Antibody Measured by enzyme-linked immunosorbent assay (ELISA) Up to 28 days after second vaccination
Secondary Geometric Mean Fold Rise (GMFR) of SARS-CoV-2 Surrogate Viral Neutralising Antibody Measured by enzyme-linked immunosorbent assay (ELISA) Up to 28 days after second vaccination
Secondary Seroconversion Rate of SARS-CoV-2 Surrogate Viral Neutralising Antibody Seroconversion Rate is defined as a greater than or equal to 4-fold rise in SARS-CoV-2 surrogate viral neutralising antibody from baseline Up to 28 days after second vaccination
Secondary Geometric Mean Titer (GMT) of RBD-specific IgG Antibody Measured by enzyme-linked immunosorbent assay (ELISA) Up to 28 days after second vaccination
Secondary Geometric Mean Fold Rise (GMFR) of RBD-specific IgG Antibody Measured by enzyme-linked immunosorbent assay (ELISA) Up to 28 days after second vaccination
Secondary Seroconversion Rate of RBD-specific IgG Antibody Measured by enzyme-linked immunosorbent assay (ELISA). Seroconversion Rate is defined as a greater than or equal to 4-fold rise in RBD-specific IgG Antibody from baseline Up to 28 days after second vaccination
Secondary Percentage of participants who have positive RBD-specific CD4+ and CD8+ T-cell IFN-y ELISpot responses Measured by IFN-y ELISpot assay Up to 28 days after second vaccination
Secondary Median number of spot-forming cells (SFC) per 1 million PBMCs Measured by IFN-y ELISpot assay Up to 28 days after second vaccination
Secondary Percentage of participants who shows positive specific T-helper 1 responses, or T-helper 2 responses Quantified by Intracellular Cytokine Staining Up to 28 days after second vaccination
Secondary Medium percentage of specific T-helper 1 responses or T-helper 2 responses Quantified by Intracellular Cytokine Staining Up to 28 days after second vaccination
See also
  Status Clinical Trial Phase
Completed NCT05065827 - Lung Ultrasound Findings in Patients With COVID-19 in a UK ED
Recruiting NCT05359770 - Association of Inspiratory Muscle Training With HD-tDCS for Assistance to Patients With Long Covid-19 N/A
Completed NCT04515147 - A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19 Phase 2
Not yet recruiting NCT06025812 - Clinical Study of Omicron BA.4/5-Delta Strain Recombinant Novel Coronavirus Protein Vaccine (CHO Cells) N/A
Recruiting NCT05289115 - Protocol for Assistance to Patients With Long Covid-19 Undergoing Treatment With HD-tDCS N/A
Completed NCT04779138 - Increasing Vaccine Uptake in Underresourced Public Housing Areas N/A
Not yet recruiting NCT05868239 - Impact of Aerosol Box Use During Cardiopulmonary Arrest: A Multicenter Study N/A
Completed NCT04690413 - NOWDx Test for the Detection of Antibodies to COVID-19 N/A
Completed NCT04818164 - Prone Position Improves End-Expiratory Lung Volumes in COVID-19 Acute Respiratory Distress Syndrome
Terminated NCT04530448 - Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization Phase 4
Completed NCT04572399 - UVA Light Device to Treat COVID-19 N/A
Recruiting NCT04610567 - Treatment of Patients With Mild Coronavirus-19 (COVID-19) Disease With Methotrexate Associated to LDL Like Nanoparticles (Nano-COVID19) Phase 1/Phase 2
Recruiting NCT04772170 - Observational Digital Biomarker Discovery in Respiratory Virus Challenge Studies
Recruiting NCT04581954 - Inflammatory Signal Inhibitors for COVID-19 (MATIS) Phase 1/Phase 2
Completed NCT04405934 - COG-UK Project Hospital-Onset COVID-19 Infections Study N/A
Enrolling by invitation NCT04484025 - SPI-1005 Treatment in Moderate COVID-19 Patients Phase 2
Completed NCT05572840 - Wear Your Mask, Wash Your Hands, Don't Get COVID-19 N/A
Withdrawn NCT04838847 - A Study to Evaluate the Immunogenicity and Safety of the SARS-CoV-2 mRNA Vaccine CVnCoV in Elderly Adults Compared to Younger Adults for COVID-19 Phase 3
Completed NCT04556149 - imPulse™ Una Full-spectrum, Over Clothing E-stethoscope
Terminated NCT04371978 - Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19 Phase 3